PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript Summary
PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript Summary
Net loss improved significantly from $3.7 million last year to $2.2 million this quarter.The following is a summary of the PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript:
以下是PetVivo Holdings, Inc. (PETV) 2025年第二季度业绩会议记录总结：
Financial Performance:
财务表现：
PetVivo reported a sequential revenue growth of 62% in the fiscal second quarter, primarily driven by a 147% increase in distributor sales.
The company achieved a gross profit margin of 89.5%.
Net loss improved significantly from $3.7 million last year to $2.2 million this quarter.
Operating expenses declined by 25% due to strategic company-wide reduction and restructuring programs.
PetVivo报告，由经销商销售增长147％主导，公司第二季度财政营业收入环比增长62％。
公司的毛利润率达到89.5％。
净亏损较去年的370万美元显著改善，本季度降至220万美元。
由于战略性全公司减少和重组计划，营业费用下降了25％。
Business Progress:
业务进展：
PetVivo expanded the distribution of its flagship product, Spryng, which has now reached over 800 clinics across all 50 states.
New clinical trials, including an elbow study for dogs with osteoarthritis, are underway, enhancing the product's validation and adoption.
Significant staffing increases in sales and marketing roles have been made to support growth, especially aimed at the companion animal market.
PetVivo participated in major veterinary conferences and events, boosting visibility and advocacy for its Spryng product among veterinary professionals.
PetVivo扩大了旗舰产品Spryng的分销范围，目前已覆盖50个州的800多家诊所。
新的临床试验，包括关于患有骨关节炎的狗的肘部研究正在进行中，将增强该产品的验证和采用。
已经加大了销售和市场营销岗位的重要人员配备，以支持增长，特别是针对伴侣动物市场。
PetVivo参加了主要的兽医会议和活动，提升了Spryng产品在兽医专业人士中的知名度和推广。
Opportunities:
机会：
The expansion into the companion animal market, a significantly larger market segment, aims at driving future revenue growth.
Continued collaboration with leading R&D companies, like Orthobiologic Innovations, for product development and clinical trials to enhance product adoption.
进军伴侣动物市场，这一规模显著较大的市场细分，旨在推动未来营业收入增长。
与Orthobiologic Innovations等领先的研发公司继续合作，以进行产品开发和临床试验，以增强产品的采用。
Risks:
风险：
Transition from smaller equine markets to companion animal markets involves risk of market acceptance and operational adjustments.
从较小的马匹市场转向伴侣动物市场，涉及市场接受风险和运营调整。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
